STOCK TITAN

CRISPR Therapeutics (CRSP) Stock News

CRSP NASDAQ

CRISPR Therapeutics AG reports developments in gene-based medicines built around CRISPR/Cas9 gene editing, cell therapy, in vivo editing and siRNA programs. Recurring updates cover CASGEVY, developed with Vertex for severe sickle cell disease and transfusion-dependent beta thalassemia, as well as pipeline work in cardiovascular disease, autoimmune disease, oncology, rare disease and Type 1 diabetes.

Company news also includes financial results, business updates, investor conference presentations, manufacturing and platform disclosures, collaborations such as Sirius Therapeutics, and capital actions involving common shares or convertible senior notes.

Rhea-AI Summary

CRISPR Therapeutics (CRSP) announced that senior management will participate in a fireside chat at the Jefferies Global Healthcare Conference on November 17, 2026.

The session starts at 10:00 a.m. GMT. A live webcast will be available through the Events & Presentations page in the Investors section of the company’s website, with a replay archived for 14 days following the presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.77%
Tags
none
-
Rhea-AI Summary

CRISPR Therapeutics (Nasdaq: CRSP) presented Phase 1b CTX310 data showing a mean triglyceride reduction of 63% in patients with severe hypertriglyceridemia.

The open-label cohort included 10 participants with median baseline triglycerides above 1,000 mg/dL. At Day 30, a single-course treatment reduced circulating ANGPTL3 protein by a mean 65%, non-HDL cholesterol by 51% and apolipoprotein B by 23%. LDL cholesterol fell 16% from a low mean baseline of 60 mg/dL. ANGPTL3 and triglyceride reductions were maintained in participants followed for at least 90 days.

No treatment-related serious or Grade 3 or higher adverse events occurred; one Grade 2 infusion reaction resolved. Seven participants had at least 90 days of follow-up. The FDA granted RMAT designations for severe hypertriglyceridemia and elevated LDL cholesterol. Additional Phase 1b cohorts remain ongoing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
-
Rhea-AI Summary

CRISPR Therapeutics (Nasdaq: CRSP) reported Phase 1 zugo-cel results showing clinical responses across refractory rheumatologic autoimmune disease cohorts. At the July 21, 2026 cutoff, 83% (5/6) of systemic sclerosis patients receiving standard lymphodepletion, a preparatory immune-cell reduction regimen, achieved an rCRISS-25 clinical response at Month 3. All five maintained response; four had at least six months of follow-up.

By October 15, 2026, 21 patients had been dosed. All nine with inflammatory muscle disease achieved moderate or major Total Improvement Score responses. Two of three evaluable lupus patients maintained drug-free DORIS remission through at least Month 9. No dose-limiting toxicities, severe infections or deaths were reported; cytokine release syndrome did not exceed Grade 2. Dose escalation continues, with higher CAR-T cell expansion in six patients receiving 200 million CAR+ cells than at 100 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
none
Rhea-AI Summary

CRISPR Therapeutics (CRSP) will present zugo-cel clinical data in large B-cell lymphoma at ASH on December 13, 2026. The oral presentation covers the ongoing Phase 1/2 trial in patients whose disease has returned or has not responded to treatment. Zugo-cel is an investigational gene-edited CAR T-cell therapy made from donor cells and targeting CD19.

The presentation is scheduled for 5:15 p.m. CST. A copy will be available on the company website after it concludes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
-
Rhea-AI Summary

CRISPR Therapeutics (CRSP) reported a third-quarter 2026 net loss of $111.4 million alongside higher CASGEVY sales and progress across its pipeline. The loss widened from $106.4 million a year earlier. CASGEVY revenue reached $99 million, up 30% quarter-over-quarter and nearly six times the year-earlier level; this is product revenue, not CRISPR Therapeutics’ reported revenue. Cash, cash equivalents and marketable securities totaled $2,276.6 million at September 30, versus $1,975.8 million at year-end 2025, supported by convertible-note proceeds.

CASGEVY gained approvals for younger children in additional countries. The FDA granted CTX310 regenerative medicine designations for severe hypertriglyceridemia and elevated LDL cholesterol. CTX611 completed Phase 2 enrollment. CRISPR Therapeutics plans to present CTX310 data on November 9 and zugo-cel systemic sclerosis data on November 8, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
-
Rhea-AI Summary

CRISPR Therapeutics (Nasdaq: CRSP) appointed Sivakesava (Siva) Sakhamuri, Ph.D., as Chief Technical Officer, effective immediately on November 2, 2026.

Sakhamuri brings about 30 years of technical operations and manufacturing leadership experience. He joins from Orna Therapeutics, where he served as Chief Technical Officer since 2024, leading its manufacturing development and quality organizations. Previously, he headed technical operations and quality at Omega Therapeutics. At Alnylam Pharmaceuticals, he led manufacturing readiness for the commercial launch of three RNA interference therapeutics and managed construction of an internal oligonucleotide manufacturing facility.

Across his career, Sakhamuri has managed or supported 10 marketing application submissions and nine investigational drug applications, and contributed to eight product launches.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
none
Rhea-AI Summary

CRISPR Therapeutics (CRSP) appointed A.J. Silver to succeed Raju Prasad as Chief Financial Officer, effective October 19, 2026.

The company said Prasad is stepping down to pursue external opportunities. Silver has served as Senior Vice President of Finance since January 2025 and joined CRISPR Therapeutics in October 2018. His responsibilities have included treasury, financial planning and analysis, accounting and reporting, tax, and financial operations. Before joining the company, he spent more than 10 years at Ernst & Young, where he became a Certified Public Accountant.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
none
-
Rhea-AI Summary

CRISPR Therapeutics (CRSP) will present Phase 1b clinical data for CTX310 at the American Heart Association Scientific Sessions on November 9, 2026. The late-breaking oral presentation covers patients with severe hypertriglyceridemia, a condition involving very high blood triglyceride levels. CTX310 is an investigational gene-editing therapy targeting angiopoietin-related protein 3 (ANGPTL3).

The presentation is scheduled for 8:00 a.m. CST during the session “New Frontiers in Cardiometabolic Risk Reduction.” The data remain embargoed until the presentation begins. A copy of the presentation will be available on the company's website after it concludes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
none
-
Rhea-AI Summary

CRISPR Therapeutics (CRSP) will present Phase 1 zugo-cel data in refractory systemic sclerosis at ACR Convergence on November 8, 2026. The poster, titled “Safety and Efficacy of Anti-CD19 Allogeneic Chimeric Antigen Receptor (CAR) T Cell Therapy Zugocabtagene Geleucel (zugo-cel) in Patients with Refractory Systemic Sclerosis,” is scheduled for 10:30 a.m. ET in Poster Session A, abstract 0225.

Zugo-cel is an investigational, gene-edited immune-cell therapy targeting CD19. It is being evaluated in Phase 1 trials across rheumatologic, hematologic and neurologic autoimmune indications. The presentation will be available at crisprtx.com after it concludes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
Rhea-AI Summary

CRISPR Therapeutics (CRSP)/b) announced that senior management will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, at 1:05 p.m. EST.A live webcast of the fireside chat will be available on the Investors "Events & Presentations" page of the company website, with a replay accessible for 14 days after the presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
none

FAQ

What is the current stock price of CRISPR Therapeutics (CRSP)?

CRISPR Therapeutics (CRSP) last closed at $42.24.

What is the market cap of CRISPR Therapeutics (CRSP)?

The market cap of CRISPR Therapeutics (CRSP) is approximately $4.1B.